A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Tarsus Pharmaceuticals, Inc. TARS
Promising (early) broader-coverage candidate · Tarsus Pharmaceuticals, Inc.
On FrontierLab's discovery record since 2026-07-10 (6 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-19), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 105.2% |
|---|---|
| Gross margin | 90.6% |
| Gross profits / assets | 0.9 |
| Rule of 40 | 97.2 |
| Net margin | -8% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 5 |
Quality checklist
- ✓ Revenue growth — 105.2% (pass ≥ 20%)
- ✓ Capital efficiency
- ✓ Gross margin — 90.6% (pass ≥ 60%)
- ✗ Gross-margin trend — -2.8 (pass ≥ 2)
- ✓ Share dilution — 2.4%
Fundamentals — snapshot as of 2026-08-19
| Stage | Early |
|---|---|
| Share issuance (YoY) | 2.4% · modest issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-1.09 |
| Burn multiple | — |
| Gross-margin trend (pts) | -2.8 |
| Cash / assets | 0.74 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-06 |
Momentum context — a snapshot from 2026-08-19, not current
| Price at surface | $71.03 (as of 2026-08-19) |
|---|---|
| 52-week range | $48.2 – $85.25 |
| % off 52-wk high | -16.7% |
| RSI (14) | 69 |
| Relative volume | 0.8× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-19 (end-of-day). How grades are computed →